Crohn’s & Colitis Foundation Honors Three Scientific Leaders for Exceptional Contributions to Field of Inflammatory Bowel Diseases
New York, NY – The Crohn’s & Colitis Foundation of America is proud to honor three leaders in the field of IBD research and treatment on Friday, December 2nd at its 2011 Advances in Inflammatory Bowel Diseases Clinical & Research Conference (www.AdvancesInIBD.com) in Hollywood, Florida.
The award recipients – Richard P. MacDermott, MD, FACP, AGAF, MACG, Stephen B. Hanauer, MD, and Charles O. Elson, III, MD – were nominated by CCFA’s National Scientific Advisory Committee (NSAC) for their exceptional dedication to improving the quality of life for the 1.4 million Americans afflicted with Crohn’s disease and ulcerative colitis, two painful, debilitating, lifelong digestive diseases collectively known as inflammatory bowel diseases (IBD).
Dr. MacDermott, Thomas Ordway, MD Distinguished Chair in Medicine, Director of the Inflammatory Bowel Diseases Center and Professor of Medicine at Albany Medical College, is the recipient of CCFA’s prestigious Henry D. Janowitz Lifetime Achievement Award in IBD for his unwavering commitment and pursuits in the field. This award is presented annually to the research scientist who has demonstrated a career-long dedication toward a deeper understanding of these devastating diseases. During the last four decades, Dr. MacDermott’s research has pushed the boundaries of scientific knowledge, with particular emphasis on the role of the immune system in inflammatory bowel disease. He has published more than 120 original scientific publications, plus more than 80 review articles and chapters in this area. In addition, Dr. MacDermott has been actively involved with CCFA, as former Chair of the Research Grants Committee, Chairman of the National Scientific Advisory Committee, as well as Founding Co-Editor of CCFA’s premier professional journal devoted to advances in Crohn’s and colitis research – Inflammatory Bowel Diseases. As founding Co-Chair of the Advances conference, Dr. MacDermott has helped expand research and education in IBD worldwide.
Dr. Hanauer, Joseph B. Kirsner Professor of Medicine and Clinical Pharmacology, Chief of the Section of Gastroenterology, Hepatology and Nutrition at the University of Chicago Pritzker School of Medicine, and Director of the Logan Center for Gastrointestinal Research, is no stranger to exploring the frontier of knowledge in the field of IBD. For his steadfast and continious contribution to advancing discoveries in IBD management and treatment, Dr. Hanauer was selected to receive the CCFA Scientific Achievement in Clinical Research Award. Among his many accomplishments in the IBD field, Dr. Hanauer has authored hundreds of peer-reviewed journal articles, books and book chapters. He has also designed and maintains a 7,000-patient registry database for inflammatory bowel diseases. Dr. Hanauer’s involvement with CCFA includes his prior role as Inaugural Chair of CCFA’s Clinical Alliance and membership in the Nation Scientific Advisory Committee. He is also Co-Chair of the Advances conference, alongside Dr. MacDermott.
Dr. Elson is Basil I. Hirschowitz Chair of Gastroenterology, as well as Professor of Medicine and Microbiology at the University of Alabama at Birmingham. Dr. Elson has a lengthy career of accomplishments that have left a defining mark on the IBD field, with a primary focus on research into the regulation of the mucosal immune response in the intestine, including mechanisms of mucosal immunity, tolerance and inflammation. Alongside colleagues, one of Dr. Elson’s crowning achievements includes pioneering the use of mouse models of IBD, including the C3H/HeJBir line, a
CCFA initiative. Actively involved in numerous medical societies and professional organizations, including American Gastroenterological Association, Association of American Physicians, American Academy of Microbiology and has authored numerous papers in the field.
“The Crohn’s & Colitis Foundation is excited to honor these three highly-distinguished members of the scientific community whose contributions to the field of IBD research set a high benchmark among their peers” says Richard J. Geswell, President of the Crohn’s & Colitis Foundation. “We value their impact on research and education, and eagerly await their future contributions in the quest for improved IBD treatments and ultimately cures.”
About Crohn's Disease and Ulcerative Colitis
Crohn's disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn's disease or ulcerative colitis, with as many as 150,000 under the age of 18. Most people develop the diseases between the ages of 15 and 35.
About Advances in IBD, Crohn's & Colitis Foundation's Clinical & Research Conference
The Advances in Inflammatory Bowel Disease, Crohn's & Colitis Foundation's Clinical & Research Conference has grown to become the foremost annual event for investigators and clinicians in the field of IBD. This conference allows professionals to come together, share their knowledge and experience, as well as learn about the latest advances and determine future priorities as related to the care and management of patients with IBD. Conference attendees gain insight from expert faculty on cutting-edge research breakthroughs and advances in IBD patient care. In 2011, more than 1,200 healthcare professionals attended the conference— the largest annual meeting in the United States dedicated to the state-of-the-art research and management of patients with IBD. Visit www.advancesinibd.com for more information.
Crohn’s & Colitis Foundation
Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 80 cents of every dollar the Foundation spends going to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org).